Objective To compare macular choroidal thickness between cigarette smokers, those with a history of smoking, and nonsmokers in patients over 65 years of age with earlyatrophic age-related macular degeneration (AMD) and normals. Methods Prospective, consecutive, observational case series. Enhanced depth imaging spectral domain optical coherence tomography 12-line radial scans were performed and choroidal thickness manually quantified at 84 points in the central 3 mm of the macula. Data of normals, soft drusen alone, and soft drusen with additional features of early AMD were compared. A multivariate analysis of variance (MANOVA) model, controlling for age, was constructed to evaluate the effect of smoking history and AMD features on choroidal thickness. Results A history of smoking was significantly associated with a thinner choroid across all patients via logistic regression (P ¼ 0.004; O.R. ¼ 12.4). Mean macular choroidal thickness was thinner for smokers (148±63 mm) than for nonsmokers (181±65 mm) among all diagnosis categories (P ¼ 0.003). Subgroup analysis of patients with AMD features revealed a similar decreased choroidal thickness in smokers (121 ± 41 mm) compared with nonsmokers (146 ± 46 mm, P ¼ 0.006). Bivariate analysis revealed an association between increased pack-years of smoking and a thin choroid across all patients (Po0.001) and among patients with features of early AMD (Po0.001). Both the presence of features of macular degeneration (Po0.001) and a history of smoking (P ¼ 0.024) were associated with decreased choroidal thickness in a MANOVA model.
Introduction
Age-related macular degeneration (AMD) is a degenerative macular condition with both atrophic and neovascular subtypes and is the most common cause of severe vision impairment in adults over 65 years of age in the United States and Europe. Multiple risk factors including age, dietary antioxidant intake, 1 genotype, 2 and smoking have been identified in several large cohorts of affected patients. 3, 4 Cigarette smoking is a highly prevalent modifiable risk factor for many pulmonary, cardiovascular, and additional systemic diseases. Smoking may be related to the development of AMD, [5] [6] [7] and has consistently been shown to lead to increased risk of all late forms of AMD. 1, [8] [9] [10] [11] [12] [13] Smoking has also been demonstrated to increase the risk of choroidal neovascularization owing to polypoidal choroidal vasculopathy, 14 or ocular histoplasmosis. 15 There is little direct evidence for the specific mechanism by which smoking leads to increased risk in AMD, however oxidative stress and vascular injury have been proposed.
Recently, particularly with the advent of enhanced depth imaging optical coherence tomography (EDI), 16, 17 there have been many reports of choroidal thickness and morphology in retinal diseases. Known factors affecting choroidal thickness are age, 18, 19 axial length, 19, 20 specific medications, 21 and chorioretinal disorders such as central serous chorioretinopathy. 22 Patients with high myopia, 18, 23 diabetic retinopathy, 24 and age-related choroidal atrophy 25 appear to have a particularly thin choroid.
Consistent with some previous reports, 26, 27 we have recently observed decreased choroidal thickness among patients with typical soft drusen, subretinal drusenoid deposits, and early-atrophic age-related macular degeneration compared with normals. 28 Cigarette smoking has been linked to many vascular alterations, including experimental evidence of altered retinal 29 and choroidal 30, 31 blood flow, and endothelial reactivity. Smokers may also be at higher risk for the development and severity of choroidal neovascularization. 7, 32 We hypothesized that smokers may have distinct choroidal anatomic features that may include an overall thin choroid. The purpose of the present study was to evaluate central macular choroidal thickness among patients with drusen, early-atrophic AMD, and normals.
Materials and methods
This prospective, consecutive, observational case series conformed to the tenets set forth in the Declaration of Helsinki and was performed in accordance with the Health Insurance Portability and Accountability Act of 1996. The study was approved by the institutional review board of the University of Tennessee, Memphis Health Sciences Center. All patients were seen and examined at the Charles Retina Institute, Memphis, TN.
Patients
Consecutive patients were recruited at a regularly scheduled office visit for EDI SD-OCT examination after meeting the following inclusion criteria:
1. Age greater than 65 years.
2. No previous eye disease other than refractive error, cataract extraction with intact posterior capsule, drusen, or early-atrophic macular degeneration.
3. No history of diabetes or uncontrolled hypertension; no additional uncontrolled systemic disease; blood pressure measurement on day of EDI o140 systolic and o90 diastolic. 4. Spherical equivalent (autorefraction of either phakic patients or measured before cataract extraction) ±2.00 diopters.
5.
No anti-VEGF therapy in fellow eye for at least 3 months before EDI.
6. Intraocular pressure between 11 and 19 mm Hg as measured by Goldmann applanation tonometry on the day of EDI examination.
7. Willing to undergo informed consent for study participation.
The spectrum of early AMD was divided to include those with drusen alone as well as those with drusen plus additional features of early AMD such as subretinal drusenoid deposits and RPE hyperpigmentation. Earlyatrophic AMD was defined as the presence of largemacular soft drusen with RPE hyperpigmentation as seen by ophthalmoscopy and fundus photography. Subretinal drusenoid deposits and focal areas of outer retinal atrophy on SD-OCT were considered part of the atrophic AMD group. Patients with Snellen bestcorrected visual acuity less than 20/200 in the study eye or any geographic atrophy were excluded. Patients with a history of choroidal neovascularization in the fellow eye were not specifically excluded. The drusen group had the presence of macular soft drusen greater than 125 mm without evidence of hyperpigmentation or RPE atrophy on fundus photography, and no evidence of outer retinal or RPE atrophy on SD-OCT. Patients in the drusen and AMD group must have had an available fluorescein angiogram within the past 6 months, and patients with any evidence of neovascularization or geographic atrophy in the study eye were excluded. Thus, rather than using a traditional classification system, 4, 33 we modified this using combined fundus photographic, angiographic, and SD-OCT criteria. Normals were recruited from patients presenting for fundus examination with a unilateral disease process or no eye disease.
Imaging
The EDI protocol performed in the present study has been previously described. 28 Briefly, all images were obtained by a single experienced ophthalmic photographer, and quantifications were performed independently by two observers (authors EJS and JCR). Spectralis (Heidelberg Engineering, Heidelberg, Germany) 12-line radial raster scan pattern was performed using the enhanced depth imaging optical coherence tomography (EDI) function with 20 scans averaged per raster. A single observer (author EJS.) initially screened scans for image quality and the absence of exclusion criteria. Autorefraction was performed on the day of each SD-OCT and entered into the Spectralis patient data entry window before each scan. Computer randomization with equal allocation ratio was used to determine which eye would be included for patients with bilateral AMD or drusen. Gray scale, brightness scan (b-scan) images were viewed on the device console. Only scans with a signal strength of at least 8/10 were included. Four scans were initially excluded owing to the low-signal strength secondary to media opacity or ocular surface disorder. The device caliper tool (Heidelberg Eye Explorer, Heidelberg Engineering) was used to perform all measurements. Initially, a single subfoveal choroidal thickness was obtained by extending the caliper tool from the inner aspect of the Bruch's membrane (outer border of RPE) to the inner scleral border. The caliper was then used to sequentially measure 500 mm distances in both radial directions and a new measurement was obtained at each location. This was performed for three radial positions in each direction for each raster, for a total of seven choroidal measurements in each raster, including the central 3 mm of the macula (84 measurements per eye). All values were then combined and averaged for the recorded overall macular CT. Representative EDI images for diagnosis categories in smokers and nonsmokers are presented in Figure 1 .
Data analysis
The data used for the present study was a subset of an ongoing prospective study, the Choroidal Thickness in Age-related Eye Disease Study, with additional details reported elsewhere. 28 For the present study, smoking history was categorized as either no history of regular cigarette smoking, current smoker, or former smoker if the patient reported at least 1 year of habitual smoking but at least 1 year free of cigarette use. Additional categorical variables including history of hypertension and history of hypercholesterolemia were also recorded. Pack-years of cigarette smoking were similarly recorded. All data was analyzed using JMP Pro 10 (SAS, Cary, NC, USA).
Initially, continuous variables were compared among diagnostic groups using one-way analysis of variance (ANOVA). Categorical variables were compared using w 2 -test or Fisher's exact test. Univariate logistic regression was used to compare categorical and continuous variables. Bivariate fit-line analysis was used to perform pairwise comparisons among continuous variables. Subgroup analysis was performed separately for normals and for those with features of AMD (drusen and atrophic AMD groups combined). We then constructed a multivariate ANOVA (MANOVA), adjusting for previously identified significant interactions, to evaluate the independent effect of smoking history. This yielded a model including AMD features and cigarette smoking status as categorical variables adjusted for the effect of age on choroidal thickness.
Results
Hundred and forty seven patients were included consisting of 38 with drusen alone, 60 patients with Eye early-atrophic AMD, and 49 normals. A summary of photographic characteristics and smoking history by diagnosis category is presented in Table 1 . Of the 147 patients included in the study, 145 patients were Caucasian and two patients were of African American origin. Mean age±standard deviation was 78±7.2 years and was not significantly different among diagnosis categories (P ¼ 0.294). Mean spherical equivalent was 0.051 ± 0.02 diopters. There were no significant differences in age among diagnosis categories (P ¼ 0.37) or mean refractive error (P ¼ 0.44). The patient cohort consisted of 10 current smokers, 57 former smokers, and 80 patients with no smoking history. Of the 147 patients included in the study, 76 of them had controlled hypertension on current medications. Mean pack-year history among smokers was 16.1 ± 14.2 years.
Smoking status was not significantly correlated with diagnosis category (P ¼ 0.096). A history of controlled hypertension (P ¼ 0.153) or hypercholesterolemia (P ¼ 0.213) was not significantly related to choroidal thickness. Graphical analysis of mean choroidal thickness by smoking category is presented in Figure 2 . Across all patients, mean choroidal thickness for smoking history (148 ± 63 mm) was significantly thinner than for normals (181 ± 65 mm, P ¼ 0.003). Univariate logistic regression revealed a significant association between a history of smoking and a thinner choroid (P ¼ 0.004, O.R. ¼ 12.4). Subgroup analysis of normals alone revealed a trend for thinner choroidal thickness in smokers (215±54 mm) than nonsmokers (237±50 mm), however the difference did not reach statistical significance (P ¼ 0.14). Subgroup analysis among patients with features of AMD (drusen or atrophic AMD) demonstrated a significantly thinner choroid for those with a history of smoking (121 ± 41 mm) than those with no smoking history (146 ± 46 mm; P ¼ 0.006). Bivariate fit-line analysis revealed a strong inverse correlation between pack-years of cigarette smoking and mean macular choroidal thickness (Po0.001). Increase in pack-years of smoking was highly correlated with the history of choroidal neovascularization in the fellow eye.(P ¼ 0.009) Graphical analysis of pack-year history of smoking and mean macular choroidal thickness is presented in Figure 3 .
Results for the MANOVA whole model test were highly significant (Po0.001). Adjusting for age, drusen (Po0.001), early AMD (Po0.001), and history of smoking (P ¼ 0.024) were independently associated with decreased mean choroidal thickness. A subgroup model including only patients with AMD, adjusted for age, revealed a history of smoking (P ¼ 0.026) and atrophic macular degeneration (Po0.001) diagnosis as factors associated with a thinner choroid.
Discussion
The results of the present study indicate that a history of cigarette smoking is associated with decreased central macular choroidal thickness among Caucasian adults over 65 years of age. Results from the univariate analysis of the Beijing Eye Study demonstrated a similar association with subfoveal choroidal thickness among adults over 50, 34 however the statistical significance was not present in the multivariate model adjusted for age and additional covariates. The present study differed in both patient demographics and method of macular choroidal thickness measurement. While Wei et al 34 reported results from a single subfoveal choroidal thickness, we obtained the average of 84 points per eye in the central 3 mm of the macula. In addition, their series examined patients over 50, a generally younger cohort than our series. These factors likely account for the observed differences in results. In the subgroup analysis, we demonstrated a significantly thinner choroid in smokers with features of early AMD, but the result was not present for normals alone. This is likely accounted for the smaller sample size and resultant reduced power for the normals alone. While features of early AMD appear to be a better predictor of reduced choroidal thickness, a history of chronic cigarette smoke exposure appears to remain a significant influential factor in the present series. AMD diagnosis was not specifically related to a history of smoking in the present series; the study was underpowered to detect this association, and the proportion of smokers in each diagnosis category was similar. We did not find a history of hypertension associated with differences in mean choroidal thickness, but included only treated patients with no history of uncontrolled hypertension. The 52% of patients with chronic, controlled hypertension is consistent with reported rates for the general population. 35 There are many potential mechanisms by which chronic cigarette smoke may influence choroidal vasculature. Cigarette smoke contains a myriad of potential toxic and systemic vasoconstrictive substances [36] [37] [38] including nicotine. 39, 40 Experimental evidence indicates that smoking induces multiple acute influences on cerebral vasculature, with vasoconstriction predominating during chronic Figure 2 Comparison of mean macular choroidal thickness (CT) among smoking categories. (a) One-way analysis of variance (ANOVA) between lifetime nonsmokers, current smokers, and former smokers; green diamonds vertically centered on mean spanning 1 SD; horizontal width proportional to sample size; mean CT as follows: nonsmokers, 181±65, n ¼ 80; current smokers, 147±61, n ¼ 10; former smokers, 149 ± 64 mm, n ¼ 57; P ¼ 0.011; (b) Two-sample t-test subgroup analysis of patients with drusen or early AMD; mean CT is as follows: nonsmokers, 146 ± 46 mm, n ¼ 49; history of smoking, 121 ± 41 mm, n ¼ 49; P ¼ 0.006. exposure. 41 Smoking appears to impair endothelial cell function in many vascular regions, and evidence supports long-term vasoconstriction and altered endothelial response 37, 42, 43 to various vasoactive mediators in tobacco smoke. 40, 44, 45 Human studies indicate abnormal choroidal vascular reactivity to carbogen (high oxygen) inhalation in chronic smokers. 30 Substances in cigarette smoke have additionally been demonstrated to induce direct oxidative damage to endothelium. 46, 47 We hypothesize that chronic cigarette smoke exposure contributes to specific structural changes to the choroid which might manifest as an overall thinner than average appearance on EDI. These manifestations may result from chronic vasoconstriction, coupled with direct oxidative damage to endothelium, leading to vascular dropout. Pack-years of smoking appear to be associated with a thinner choroid in the present study, which indicates a probable dose-dependent effect.
Previous reports have indicated an increase risk and severity of choroidal neovascularization in smokers, 5, 7, 32 which may be related to nicotine-induced increase in retinal pigment epithelial vascular endothelial growth factor. 48, 49 Similarly we observed a strong correlation between increased pack-years and a history of choroidal neovascularization in fellow eyes of those with chronic tobacco smoke exposure, indicating a dose-dependent increased risk of late AMD in smokers. Smoking has also been associated with increased risk of polypoidal choroidal vasculopathy (PCV), a process typically demonstrating a thicker than normal choroid. 32 However, it may be difficult to accurately assess choroidal thickness in the context of a neovascular process, since type 1 neovascularization adds to choroidal thickness. Additional smoking related factors may be important in PCV, such as complement factor, and VEGF alterations. The significance of choroidal thickness in AMD remains unknown. With recent advances in SD-OCT, this parameter has become a clinically measurable anatomic variable in patients with various retinal conditions. We have recently observed a thinner choroid in patients with signs of early AMD, which is consistent with some previous reports. 26, 27 Both smoking history and the presence of early AMD are associated with the development of late AMD, including both geographic atrophy and choroidal neovascularization. 1, [8] [9] [10] [11] [12] [13] 32 Therefore, choroidal thickness may be an additional useful clinical variable in assessing risk of AMD progression or the development of late AMD, particularly considering its apparent anatomic association with these two well-known risk factors. While a thin choroid is not necessarily related to blood flow or overall function, 50 there is evidence of regional choroidal blood flow alterations in AMD, [51] [52] [53] [54] [55] which may involve an overall decrease in blood flow and regional volume. 52, 53, 56 The present study is limited by small to moderate sample size, single-center study location, and predominantly Caucasian subjects. Although we made every effort to control for known variables that affect choroidal thickness, there remain many additional potentially unrecognized confounding factors. We used a classification system that included ophthalmoscopic, angiographic, and SD-OCT features to identify features of early AMD, that may differ from additional centers. We conclude that there is an apparent relationship between chronic cigarette smoke exposure and a relatively thin choroid in Caucasian patients with features of early AMD who are over 65 years of age, which is likely present in normals as well. This may be an anatomic feature underlying the increased risk of progression to late AMD in patients with a history of chronic cigarette smoking.
Summary
What was known before K Cigarette smoking is a significant risk factor for agerelated macular degeneration development and severity.
K Choroidal thickness is reduced in age-related macular degeneration.
What this study adds K Macular choroidal thickness appears to be reduced in smokers, in both normals and those with macular degeneration.
K Smoking history appears to be independently associated with macular choroidal thickness in macular degeneration.
K This anatomic variable may be linked to increased risk in cigarette smokers.
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